Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 4
2010 4
2011 6
2012 8
2013 12
2014 19
2015 30
2016 34
2017 44
2018 50
2019 67
2020 77
2021 126
2022 98
2023 110
2024 36

Text availability

Article attribute

Article type

Publication date

Search Results

570 results

Results by year

Filters applied: . Clear all
Page 1
Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib.
Kwatra SG, De Bruin-Weller M, Silverberg JI, Lio P, Deleuran M, Aydin H, Calimlim BM, Lane MC, Liu Y, Ofori S, Weidinger S. Kwatra SG, et al. Among authors: silverberg ji. Acta Derm Venereol. 2024 May 6;104:adv18452. doi: 10.2340/actadv.v104.18452. Acta Derm Venereol. 2024. PMID: 38708991
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis.
Simpson EL, de Bruin-Weller M, Hong HC, Staumont-Sallé D, Blauvelt A, Eyerich K, Gooderham M, Shahriari M, Mallbris L, Atwater AR, Rueda MJ, Ding Y, Liu Z, Agell H, Silverberg JI. Simpson EL, et al. Among authors: silverberg ji. Dermatol Ther (Heidelb). 2024 May 3. doi: 10.1007/s13555-024-01158-4. Online ahead of print. Dermatol Ther (Heidelb). 2024. PMID: 38700646
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies.
Eichenfield LF, Simpson EL, Papp K, Szepietowski JC, Blauvelt A, Kircik L, Silverberg JI, Siegfried EC, Kuligowski ME, Venturanza ME, Kallender H, Ren H, Paller AS. Eichenfield LF, et al. Among authors: silverberg ji. Am J Clin Dermatol. 2024 May 2. doi: 10.1007/s40257-024-00855-2. Online ahead of print. Am J Clin Dermatol. 2024. PMID: 38698175
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2).
Simpson EL, Prajapati VH, Leshem YA, Chovatiya R, de Bruin-Weller MS, Ständer S, Pink AE, Calimlim BM, Lee WJ, Teixeira H, Ladizinski B, Hu X, Yang Y, Liu Y, Liu M, Grada A, Platt AM, Silverberg JI. Simpson EL, et al. Among authors: silverberg ji. Dermatol Ther (Heidelb). 2024 May 2. doi: 10.1007/s13555-024-01157-5. Online ahead of print. Dermatol Ther (Heidelb). 2024. PMID: 38696027
Nonmedical Adhesive Allergens: Retrospective Analysis of Cross-Sectional Data From the North American Contact Dermatitis Group, 2001-2018.
Atwater AR, Bembry R, Green CL, Warshaw EM, Belsito DV, DeKoven JG, Reeder MJ, Silverberg JI, Taylor JS, DeLeo VA, Sasseville D, Pratt MD, Zug KA, Dunnick C, Houle MC. Atwater AR, et al. Among authors: silverberg ji. Dermatitis. 2024 Apr 8. doi: 10.1089/derm.2023.0134. Online ahead of print. Dermatitis. 2024. PMID: 38593448 No abstract available.
Characterization of disease burden, treatment and comorbidities in a large, real-world cohort of patients with atopic dermatitis: The CorEvitas Atopic Dermatitis Registry.
Silverberg JI, Cronin A, Jones EA, Dave SS, McLean RR, Greenberg J, Strober B, Bieber T, Gooderham M, Paller AS, Simpson EL. Silverberg JI, et al. JAAD Int. 2024 Feb 12;15:127-130. doi: 10.1016/j.jdin.2023.11.015. eCollection 2024 Jun. JAAD Int. 2024. PMID: 38545488 Free PMC article. No abstract available.
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2).
Silverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS, Hijnen D, Calimlim BM, Lee WJ, Teixeira HD, Hu X, Zhang S, Yang Y, Grada A, Platt AM, Thaçi D. Silverberg JI, et al. Am J Clin Dermatol. 2024 May;25(3):485-496. doi: 10.1007/s40257-024-00853-4. Epub 2024 Mar 25. Am J Clin Dermatol. 2024. PMID: 38528257 Free PMC article. Clinical Trial.
Expert Recommendations on Use of Topical Therapeutics for Vitiligo in Pediatric, Adolescent, and Young Adult Patients.
Renert-Yuval Y, Ezzedine K, Grimes P, Rosmarin D, Eichenfield LF, Castelo-Soccio L, Huang V, Desai SR, Walsh S, Silverberg JI, Paller AS, Rodrigues M, Weingarten M, Narla S, Gardner J, Siegel M, Ibad S, Silverberg NB. Renert-Yuval Y, et al. Among authors: silverberg ji. JAMA Dermatol. 2024 Apr 1;160(4):453-461. doi: 10.1001/jamadermatol.2024.0021. JAMA Dermatol. 2024. PMID: 38477910 Review.
570 results